CNBX Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 31, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Revenue	-	-	0.13	0.41	0.03	-
Revenue Growth	-	-	-68.29%	1269.13%	318.58%	-
Gross Profit	-	-	0.13	0.41	0.03	-
Selling, General & Admin	0.43	0.27	0.52	0.91	1.8	0.83
Research & Development	-	-	0.19	0.43	1.18	1.77
Operating Expenses	0.43	0.27	0.71	1.34	2.98	2.6
Operating Income	-0.43	-0.27	-0.58	-0.93	-2.95	-2.6
Interest Expense	-0.03	-0.04	-0.02	-0	-0	-0
Currency Exchange Gain (Loss)	-0	-0	-0	0	-0.06	-0.02
Other Non Operating Income (Expenses)	-	-	-	-0.05	-0.72	-0.96
EBT Excluding Unusual Items	-0.46	-0.31	-0.61	-0.98	-3.74	-3.59
Gain (Loss) on Sale of Investments	-	-	-	-	-	0.2
Gain (Loss) on Sale of Assets	-	-	-0.09	-2.73	0.01	0.2
Pretax Income	-0.46	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income	-0.46	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income to Common	-0.46	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	811	91	30	9	1	1
Shares Outstanding (Diluted)	811	91	30	9	1	1
Shares Change	2258.06%	199.69%	242.76%	621.77%	5.92%	2.95%
EPS (Basic)	-0.00	-0.00	-0.02	-0.42	-3.05	-2.77
EPS (Diluted)	-0.00	-0.00	-0.02	-0.42	-3.05	-2.77
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-0.15	-0.17	-0.25	-0.11	-1.68	-2.49
Free Cash Flow Per Share	-	-0.00	-0.01	-0.01	-1.38	-2.16
Gross Margin	-	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-	-448.31%	-227.07%	-9860.37%	-
Profit Margin	-	-	-534.46%	-904.57%	-12428.23%	-
Free Cash Flow Margin	-	-	-188.71%	-27.43%	-5610.68%	-
EBITDA	-	-0.2	-0.51	-0.77	-2.76	-2.38
EBITDA Margin	-	-	-	-187.56%	-	-
D&A For EBITDA	-	0.07	0.07	0.16	0.2	0.22
EBIT	-0.43	-0.27	-0.58	-0.93	-2.95	-2.6
EBIT Margin	-	-	-	-227.07%	-	-